MEAI: The Non-Hallucinogenic Psychedelic with an ‘Enough Switch’ for Addictions
MEAI seems to function like an “enough switch” in the brain, stopping all further desire for alcohol or cocaine and preventing overuse.
MEAI seems to function like an “enough switch” in the brain, stopping all further desire for alcohol or cocaine and preventing overuse.
In today’s episode of PsycBiz, James —the Psychedelic Investor— sits down with Mark Haden, VP of Business Development for Clearmind Medicine (CSE: CMND, OTC Pink: CMNDF, FSE: CWY0). Clearmind is a next-gen psychedelics company working on treating addiction. Their main candidate is a next-gen psychedelic called MEAI. Currently, MEAI is being researched as a treatment…
End of content
End of content
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.